Stage Technology development
Founded December 2016
Investor The Trendlines Group
CEO Maysa Mustafa
Ceretrieve’s aspiration catheter offers improved handling, enhanced clot aspiration, and improved retention of clots during removal.
This Ceretrieve catheter is indicated for use in revascularization of patients with acute ischemic stroke and is compatible with current stent retrievers.
Opportunity: The market seeks a safe, effective mechanical device to remove blood clots with easy delivery, improved aspiration, and reduced risk of distal embolization.
Send more information about Ceretrieve.
10+ years’ experience in medical product development, in various medical fields; MBA, Tel Aviv University; BSc, biomedical engineering, Technion-Israel Institute of Technology
Director of interventional cardiology, Carmel Medical Center, Haifa, Israel; assistant professor, Faculty of Medicine, Technion-Israel Institute of Technology; medical device entrepreneur (CoNavi, CardioFlow)
Israeli certified patent attorney; medical device entrepreneur (CardioFlow); BSc, mechanical engineering, MBA Technion-Israel Institute of Technology
The use of mechanical devices to remove blood clots (thrombectomy) has become the standard of care for the treatment of acute ischemic stroke patients with large vessel occlusions. The purpose of these devices – stent retrievers and aspiration catheters – is to quickly extract clots, restore blood flow (revascularization), and achieve good clinical outcomes.
Despite technological advances with current thrombectomy devices, successful revascularization is not always feasible (Neurosurgical Focus, 42:4, April 2017).
Today, physicians are forced to choose between deploying expensive, cumbersome stent retrievers that may increase the risk of emboli release or taking a quicker approach: inserting aspiration catheters that are difficult to “steer” and advance through the arteries and have limited ability to provide efficient aspiration.
According to Lawrence Biegelsen, a senior analyst at Wells Fargo Securities (“DAWN Trial Likely Positive for Stroke Market,” March 2017), in the United States alone there are over 290,000 ischemic stroke patients with large vessel occlusion. This number is expected to grow to >330,000 by 2021.There is great potential in this market as it is under-served. In 2016, only 23,000 stroke thrombectomy procedures were performed, with expected number of procedures to exceed 49,000 by 2021.